Jesse Salk

About Jesse Salk

Jesse Salk is a director at CytoTerra.

Form D filings also name Jesse Salk as a director at Cellens and a chief executive officer and director at TwinStrand Biosciences.

Jesse Salk first appears on SEC filings in 2016.

Experience

This experience comes from Jesse Salk's profile and from SEC filings. For roles taken from filings, the years are when the filings name Jesse Salk in the role, so the role may have started earlier or lasted longer.

FH

Fred Hutch Current

Affiliate Associate Professor

2026 – Present

CytoTerra Inc. Current

Co-Founder (2025 – Present)

Director

2025 – Present · Seattle, WA

Cancer testing services for clinicians and research teams.

SP

Seastone Pharma Current

Co-Founder

2025 – Present

TB

Talus Bio Current

Independent Board Director

2025 – Present

TH

The National Institutes of Health Current

Senior Principle Scientific Advisor

2025 – Present

C

Cellens, Inc. Current

Independent Board Director

2024 – Present · Boston, MA

GL

Green Umber LLC Current

President

2023 – Present

CL

Creative Destruction Lab Current

Mentor

2021 – Present

UA

U.S. Department of Veterans Affairs Current

Attending Physician, Medical Oncology

2017 – Present

TB

TwinStrand Biosciences, Inc. Current

Chief Executive Officer and director

Co-Founder (2015 – Present)

2015 – Present · Seattle, WA

UM

University of Washington - School of Medicine Current

Clinical Associate Professor, Division of Hematology and Oncology (2017 – Present)

Fellow, Division of Hematology and Oncology (2012 – 2017)

2012 – Present

Key Colleagues at Startups

The people Jesse Salk works with at each company, as listed on that company's latest Form D.

Sources

1. SECCytoTerra Inc. Form D, filed Oct 7, 2026
2. SECCellens, Inc. Form D, filed Nov 14, 2025
3. SECTwinStrand Biosciences, Inc. Form D, filed May 12, 2021